Abstract
9009Background: Most patients (pts) with anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) NSCLC develop resistance to tyrosine kinase inhibitor (TKI) therapy, with the central nervous system (CNS) as a common site of relapse. Lorlatinib is a selective brain-penetrant ALK/ROS1 TKI active against most known resistance mutations. Methods: In Ph. I of the ongoing Ph. I/II study NCT01970865, eligible pts had ALK+ or ROS1+ NSCLC with/without brain metastases (mets) and were treatment naive or had disease progression after ≥1 TKIs. Pts received lorlatinib on day –7 and daily from day 1. Primary objective was to identify the MTD and recommended Ph. II dose (RP2D). Other objectives were safety and efficacy by RECIST v1.1, including intracranial activity. Results: Of 54 pts treated in Ph. I as of Nov 30 2015, 41 were ALK+, 12 ROS1+; and 1 with mutation status not recorded at cut-off date. Pts were heavily pretreated:27 had received >1 prior TKI, 20 1 prior TKI and 7 were TKI naive; 39 pts had CNS mets a...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
